Tapering of Phenobarbital and Switching to Alternative Medication

Introduction to Phenobarbital Tapering

The American Academy of Neurology recommends levetiracetam as the first-choice medication for transitioning due to its efficacy profile, tolerability, and lack of significant pharmacological interactions 1
The American Academy of Pediatrics suggests that continuous or intermittent anticonvulsant therapy is not recommended for children with simple febrile seizures 4

The tapering process should be monitored closely, with regular checks of serum levels of phenobarbital to ensure a controlled and predictable reduction 2
The introduction of an alternative antiepiléptico, such as levetiracetam, lamotrigina, or carbamazepina, should be done simultaneously with the tapering of phenobarbital, with monitoring of serum levels and frequency of seizures during and after the tapering process 1

The frequency of seizures in patients with epilepsy is 8-11%, directly related to inadequate levels of antiepilépticos, and close monitoring is necessary during the transition period and up to 6-8 months after completion of the taper 3
Patients and caregivers should be instructed on how to recognize and respond to recurrent seizures 1

Levetiracetam has a favorable profile of adverse effects, lack of significant pharmacological interactions, and does not require monitoring of serum levels, but may cause psychiatric side effects in some patients 1
Lamotrigina requires slow titration over several weeks and has a risk of skin rash, but has good anticonvulsant activity and a favorable cognitive profile 1
Carbamazepina has proven efficacy in partial and generalized tonic-clonic seizures but is no longer recommended as a first-line agent due to pharmacological interactions and adverse effect profile 1

In patients with brain tumors, attempts to reduce and discontinue anticonvulsants can be made within weeks after surgery if there is no tumor recurrence 1
In pediatric patients with simple febrile seizures, the risks of phenobarbital, including fatal hepatotoxicity, hyperactivity, irritability, and sleep disturbances, outweigh the benefits 4

The abrupt or too rapid withdrawal of phenobarbital can precipitate severe seizures, even in previously well-controlled patients 2
The withdrawal of phenobarbital can cause significant pharmacological interactions, including increased levels of other medications metabolized by CYP3A4, requiring dose adjustments 1, 2
Monitoring for adverse effects, including respiratory depression, hypotension, cognitive changes, and mood changes, is necessary during the tapering process and introduction of new antiepilépticos 1, 2, 5